Inge M. Svane-Marie

Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis.

Journal: Journal for immunotherapy of cancer

Published: February 09, 2026

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 24, 2025

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 31, 2025

The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma.

Journal: American journal of clinical dermatology

Published: July 03, 2025

Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.

Journal: Nature communications

Published: June 19, 2025

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Journal: British journal of cancer

Published: February 12, 2025

Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes.

Journal: Journal for immunotherapy of cancer

Published: January 23, 2025

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 23, 2025

Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 07, 2024

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

Journal: Cell reports. Medicine

Published: August 29, 2024

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 18, 2024

Biomarkers for response to TIL therapy: a comprehensive review.

Journal: Journal for immunotherapy of cancer

Published: February 05, 2024

Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis.

Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis.

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma.

The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma.

Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.

Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes.

Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers.

Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers.

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome.

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome.

Biomarkers for response to TIL therapy: a comprehensive review.

Biomarkers for response to TIL therapy: a comprehensive review.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.